|
|
|
|
| Title: “State of the Art Diabetes Management: Use of Early Insulin Therapy”
| | | AAPA Release Date: July 24, 2009 | | | AAPA Expiration Date: July 31, 2010 | | | Presented by: The American Academy of Physician Assistants | | | Funding: Supported through an educational grant from Novo-Nordisk | |
|
|
|
|
|
|
|
|
|
|
|
|
Loading...
|
|
Faculty
| Lawrence Herman, MPA, RPA-C, DFAAPA
Moderator
Physician Assistant
Senior Clinical Coordinator
Assistant Professor
Department of Physician Assistant Studies
New York Institute of Technology
Old Westbury, NY
Director, Medical Education
Island Medical Physicians, PC
Hauppauge, NY
Mr. Herman is an Assistant Professor (with tenure) and Senior Clinical Coordinator in the Department of Physician Assistant Studies at New York Institute of Technology, New York College of Osteopathic Medicine affiliation in Old Westbury. He is also Vice President of Medical Education and Senior PA at Island Medical Physicians PC, in Hauppauge, New York, where he sees patients and is responsible for setting all of the practice guidelines for a large, multi-office family practice group.
He received a master of public administration in health administration and health system finance from Long Island University in Brookville, New York. He was certified by the National Commission on Certification of Physician Assistants, with special distinction in both surgery and primary care and remains certified in primary care.As a Distinguished Fellow of the American Academy of Physician Assistants, Mr. Herman has served and chaired numerous AAPA committees as well as being a Past-President of the New York State Society of Physician Assistants. He has contributed numerous book chapters to the literature and has published over 30 peer-reviewed articles. He has participated in several clinical pharmaceutical trials and continues to be an invited speaker at international and national meetings. He is the 2009 recipient of the New York Institute of Technology Annual Scholars Award for significant publication scholarship activities, the 2008 Standard of Excellence Award for providing the highest level of research and scholarship, and the 2007 and 2008 Educator of the Year award. | Charles Shaefer, Jr., MD, FACP, FCCP
Internal Medicine
Senior Partner
University Primary Care
Augusta, Georgia
Assistant Clinical Professor of Medicine
Medical College of Georgia
Augusta, Georgia
Dr. Shaefer is a senior and founding partner of University Primary Care, an Internal Medicine and Diabetes practice focused on preventive care and advanced diabetes care. He has a very busy active Internal Medicine practice focusing on all aspects of diabetes care. In addition, Dr. Shaefer is an Assistant Clinical Professor of Medicine at the Medical College of Georgia and serves as preceptor and mentor for medical students and residents. Dr. Shaefer received his undergraduate and graduate degrees from the Georgia Institute of Technology. He began medical school at the George Washington University School of Health Sciences and completed his medical degree at the Medical College of Georgia in Augusta, Georgia. He received his post-graduate medical training in Internal Medicine at the Medical College of Georgia. He is currently board-certified in Internal Medicine and has received board certification in Critical Care Medicine also. Dr. Shaefer is a Fellow in both the American College of Physicians and the American College of Chest Physicians. He is a recognized national lecturer in the area of diabetes, particularly in the primary care setting. He has addressed numerous CME conferences across the United States on the management of diabetes in the primary care setting. For a number of years he has served on the editorial board of INSULIN journal and currently is the contributing editor to that journal, writing a routine commentary on diabetes care. In addition, he has served as co-director of Taking Control Of Your Diabetes conferences and as a session chair at the 69th Annual Scientific Session of The American Diabetes Association in 2009. He has published numerous peer-reviewed articles and presented a variety of grand rounds presentations across the United States. For the last decade he has been recognized as Best Doctors in Augusta and has consistently been named to Best Doctors in America for the last decade. | Christopher M. Eten, MPAS, RPA-C
Physician Assistant
Westhampton Primary Care Center
Westhampton Beach, NY
Mr. Eten completed his Physician Assistant studies at Alderson-Broaddus College in Philippi, West Virginia in 2001. Upon graduation, he was board certified by the National Commission on Certification of Physician Assistants in both Primary Care and Surgery and remains so in Primary Care. He received his Masters Degree in 2006 from Alderson-Broaddus as well.Since 2001, Mr. Eten has worked clinically in Primary Care, Emergency Medicine, and Neurosurgery. He is currently practicing clinically at the Westhampton Primary Care center, a satellite facility of Southampton Hospital. He is a member of the American Academy of Physician Assistants as well as the New York State Society of Physician Assistants. Additionally, Mr. Eten has served on a panel to assist with the development of curriculum for the Johnson and Johnson Diabetes Institute in Milpitas, California. | |
© 2009 American Academy of Physician Assistants. All rights reserved.
|
|
|
|
| | Title: “State of the Art Diabetes Management: Use of Early Insulin Therapy” | | AAPA Release Date: July 24, 2009 | | | | AAPA Expiration Date: July 31, 2010 | | | | Presented by: The American Academy of Physician Assistants | | | Funding: Supported through an educational grant from Novo-Nordisk | | | Program Overview | The American Academy of Physician Assistants (AAPA) estimates that physician assistants (PAs) had 18,563,085 patient visits in 2008 with the diagnosis of diabetes mellitus (DM).(1) This is a staggering number considering that it is estimated that 23.6 million people or 7.8% of the population have diabetes, of which 17.9 million are diagnosed and another 5.7 million remain undiagnosed.(2) Diabetes, the metabolic syndrome, and impaired glucose tolerance (also known as pre-diabetes) are all becoming more epidemic in the United States. From 1980 through 2006, the number of Americans with diabetes tripled, and rather than slowing, this increase is rising dramatically, primarily due to the obesity epidemic in this country.(3) DM is now the 5th leading cause of death in this country and is expected to increase further.(4)
The estimated diabetes costs in the United States in 2007 include direct medical costs of $116 billion, and indirect medical costs of $58 billion, for a total of $174 billion annually. After adjusting for population age and sex differences, average medical expenditures among people with diagnosed diabetes were 2.3 times higher than what expenditures would be in the absence of diabetes.(5) Diabetes is associated with an increased risk for a number of serious, frequently life-threatening complications including acute coronary syndromes, stroke, blindness, kidney disease and death.(6) Certain populations experience an even greater threat. Good diabetes control can help reduce these risks dramatically. Type 1 diabetes mellitus (T1DM) was previously called insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes. T1DM develops when the body's immune system destroys pancreatic beta cells, the only cells in the body that make the hormone insulin that regulates blood glucose. To survive, people with type 1 diabetes must have insulin delivered by injection or a pump. In adults, T1DM accounts for 5% to 10% of all diagnosed cases of diabetes. Although it may also be treated with insulin, Type 2 diabetes mellitus (T2DM) was previously called non–insulin-dependent diabetes mellitus (NIDDM) or adult onset diabetes. In adults, type 2 diabetes accounts for about 90% to 95% of all diagnosed cases of diabetes. It usually begins as insulin resistance, a disorder in which the cells do not use insulin properly. As the need for insulin rises, the pancreas gradually loses its ability to produce it. T2DM is associated with older age, obesity, family history of diabetes, history of gestational diabetes, impaired glucose metabolism, physical inactivity, and race/ethnicity. African Americans, Hispanic/Latino Americans, American Indians, and some Asian Americans and Native Hawaiians or Other Pacific Islanders are at particularly high risk for type 2 diabetes and its complications.Gestational diabetes is a form of glucose intolerance diagnosed during pregnancy. Women who have had gestational diabetes have a 40% to 60% chance of developing diabetes in the next 5–10 years. Other types of diabetes result from specific genetic conditions (such as maturity-onset diabetes of youth), surgery, medications, infections, pancreatic disease, and other illnesses. Such types of diabetes account for 1% to 5% of all diagnosed cases.Regardless of the type of diabetes, only 37 percent of patients were achieving the American Diabetes Association's (ADA) goal for blood glucose control – a hemoglobin A1c (A1C) blood test result of less than 7 percent, ADA's recommended "take action" level. More disturbing is the fact that less than 12 percent – and some sources estimate as little as 7 percent – of people with diagnosed diabetes meet the recommended goals for blood glucose, blood pressure, and cholesterol despite a great deal of research showing that controlling these conditions dramatically delays or prevents diabetes complications.(7)There is significant data that clinicians in general do not escalate treatments in patients, termed clinical inertia.(8) In diabetes care, the largest hurdle perceived by clinicians and patients alike is the initiation of insulin therapy. In spite of not achieving goal with multiple oral anti-diabetic agents, both groups are slow to escalate to insulin, in spite of the clear benefit. Those that do initiate insulin are frequently slow to escalate dosing appropriately. In this educational initiative, an expert panel will examine and discuss the standard of care with respect to state of the art treatment of diabetes. A series of case studies will be presented to help illustrate diagnostic and therapeutic management strategies, and the critical role of PAs in managing diabetes including early initiation of insulin in clinical practice. | | References | - American Academy of Physician Assistants Annual Survey. Available at http://www.aapa.org/images/stories/iudisorders2008.pdf; Accessed July 23, 2009.
- Centers for Disease Control and Prevention, 2007 National Diabetes Fact Sheet. Retrieved December 12, 2008 from http://www.cdc.gov/diabetes/pubs/estimates07.htm
- Centers for Disease Control and Prevention, Diabetes Data and Trends. Retrieved December 12, 2008 from http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm
- American Diabetes Association. Diabetes Care. 2005;28(supply 1):S4-S36
- Centers for Disease Control and Prevention, National Diabetes Fact Sheet. Retrieved December 12, 2008 from http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf
- American Diabetes Association Diabetes Statistics. Retrieved December 12, 2008 from http://www.diabetes.org/diabetes-statistics.jsp
- National Diabetes Information Clearinghouse, Diabetes Dateline. Retrieved December 12, 2008 from http://diabetes.niddk.nih.gov/about/dateline/spr04/1.htm
- Phillips LS, Branch WT, Cook CB, et al. Ann Intern Med. 2001;135:825-834.
| | |
Faculty
| | Lawrence Herman, MPA, RPA-C, DFAAPA Moderator Physician Assistant Senior Clinical Coordinator Assistant Professor Department of Physician Assistant Studies New York Institute of Technology Old Westbury, NY Director, Medical Education Island Medical Physicians, PC Hauppauge, NY | | | Charles Shaefer, Jr., MD, FACP, FCCP Internal Medicine Senior Partner University Primary Care Augusta, Georgia Assistant Clinical Professor of Medicine Medical College of Georgia Augusta, Georgia | | | Christopher M. Eten, MPAS, RPA-C
Physician Assistant
Westhampton Primary Care Center Westhampton Beach, NY | | | Intended Audience | | Physician Assistants | | |
Clinical Dialogue Program Description
| |
In this 25 minute Webcast, an expert panel will examine and discuss the standard of care with respect to state of the art treatment of diabetes. This Internet-based CME activity includes an optional pre-and post-survey, a CME post-test and program evaluation (feedback). CME credit will be awarded to those achieving a grade of 70% or higher on the post-test.
| | |
eCase Challenge Program Description
| | Two 20 minute text-based case challenge programs will provide PAs with a review of challenging cases where they will be asked to make decisions pertaining to the management of diabetes patients. At the conclusion of each case, there is a Clinical Pearl video that the participant can view which highlights the key take away messages from each program. This Internet-based CME activity includes an optional pre-and post-survey, a CME post-test and program evaluation (feedback). CME credit will be awarded to those achieving a grade of 70% or higher on the post-test. | | | Educational Objectives | |
At the conclusion of this activity, the physician assistant should be better able to:
| - Describe the risks for acquiring T2DM, along with strategies to consider in preventing the development of T2DM.
- Detail goals of current guidelines including A1C, cholesterol, and blood pressure, along with the rationale behind these goals.
- Describe the role of the primary care health professional in helping diabetics and their families make management decisions to best control their diabetes.
- Outline management strategies for prediabetes and the early stages of T2DM, including lifestyle changes and pharmacologic choices to best treat T2DM and control sequelae of DM.
- Evaluate and modify treatment options in the face of progressive worsening of T2DM, focusing upon the role of early insulin initiation.
- Outline the management decisions that must be made in consideration of referral to a team of diabetes specialists, including a primary care provider, registered diabetes educator, and endocrinologists in any point of the disease process.
| | | Accreditation Statements |  | | Each program in this initiative has been reviewed and is approved for a maximum of 0.5 hour of AAPA Category 1 CME credit by the Physician Assistant Review Panel. Physician assistants should claim only those hours actually spent participating in the CME activity. This program was planned in accordance with the AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Approval is valid for one year from the issue date of July 24, 2009. Participants may submit the self-assessment at any time during that period. | | |
Responsibility Statement
| | The American Academy of Physician Assistants takes responsibility for the content, quality, and scientific integrity of this CME activity. | | | Faculty Disclosures | | It is the policy of the American Academy of Physician Assistants to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following: | | Lawrence Herman, MPA, RPA-C, DFAAPA, has been a consultant for Amgen, Eli Lilly and Johnson & Johnson Diabetes Institute.
| | Charles Shaefer, Jr., MD, FACP, FCCP reports receiving honoraria from Amylin-Lilly, Daiichi-Sankyo, Forest, Novo-Nordisk, Sanofi-aventis and Takeda, and has been a consultant for Novartis, Pfizer and Sanofi-aventis.
| | Christopher M. Eten, MPAS, RPA-C, reports that he has no relationship with any commercial interests whose products or services may be mentioned during this presentation.
| | | Off-Label Discussion | | There are no references to unlabelled/unapproved uses of products in this program. | | Disclaimer | | The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients. | | |
Archived Presentation
| | The Clinical Dialogue and eCase Challenge will be archived for clinicians. CME credits will be provided by the AAPA from July 24, 2009 through July 31, 2010 for physician assistants at www.AAPA.org. | | | Obtaining CME Credits | | Upon completion of your participation in the program, physician assistants will be directed to www.AAPA.org to complete a post-test and receive your certificates. | | | Successful completion of the self-assessment by physician assistants is required to earn Category 1 CME credit. Successful completion is defined as a cumulative score of at least 70% correct. Upon successful completion of the post-test, the AAPA will issue a certificate of completion for your records. | | |
Technical Requirements
| | Processor Speed: 1.4 GHz P3 | | Memory: 256 MB RAM (20MB available) | | Operating Systems Supported: Windows 2000/XP, MAC | | Browsers Supported: Internet Explorer 5.5 or greater, Mozilla Firefox and Safari 3.525 or greater | |
Additional Requirements: Flash player 8.0 or greater, 800x600 Resolution or higher with 32-bit color
| | Connection Speed: 128 Kbps or better | | Adobe Acrobat 6.0 or greater | | | Sponsored by the American Academy of Physician Assistants | 
| Supported through an educational grant from Novo-Nordisk
| | Produced by: |  | | |
© 2009 American Academy of Physician Assistants. All rights reserved.
|
|
|
| “State of the Art Diabetes Management: Use of Early Insulin Therapy” | | |
At any point in which the video is playing you can return to the Main Menu by clicking the "Back To Main Menu" button.
| |
You can submit your Feedback by clicking on the Feedback button above.
|
Technical Requirements
| | PC
| Processor Speed: 1.4 GHz P3 Memory: 256 MB RAM (20MB available) Operating Systems Supported: Windows 2000/XP, MAC Browsers Supported: Internet Explorer 5.5 or greater, Mozilla Firefox and Safari 3.525 or greater
Additional Requirements: Flash player 8.0 or greater, 800x600 Resolution or higher with 32-bit color
Connection Speed: 128 Kbps or better Adobe Acrobat 6.0 or greater
| |
MAC
|
Processor Speed: G4 processor or higher
Memory: 256 MB RAM Operating Systems Supported: OSX Browsers Supported: IE for Mac, Mozilla Firefox and Safari 3.525 or greater
Additional Requirements: Flash player 8.0 or greater
800x600 Resolution or Higher with 32-bit color.
Connection Speed: 128Kbps or better Adobe Acrobat Reader 6.0 or greater
| |
Can I watch the program without a broadband connection?
|
Yes, but your connection speed may be very slow and the quality may suffer. The setting to which the player is set for the video is auto-detected when you first launch the player.
| |
I can't see the video?
|
If you are experiencing difficulty viewing the video or player please go to www.adobe.com, download and install the latest version of Flash Player. If you continue to experience problems with Flash video consult Macromedia Flash Support at www.adobe.com.
| | © 2009 Medical Logix, LLC
|
|
|
|
|
|
|
|
|
IN ACCORDANCE WITH AAPA POLICY, PRIOR TO PARTICIPATING IN THIS ACTIVITY PLEASE REVIEW THE INFORMATION BELOW. YOU MAY LAUNCH THIS PROGRAM AT THE BOTTOM OF THIS PAGE.
|
|
|
|
|
|
|
|
|
| | Title: “State of the Art Diabetes Management: Use of Early Insulin Therapy” | | AAPA Release Date: July 24, 2009 | | | | AAPA Expiration Date: July 31, 2010 | | | | Presented by: The American Academy of Physician Assistants | | | Funding: Supported through an educational grant from Novo-Nordisk | | | Program Overview | The American Academy of Physician Assistants (AAPA) estimates that physician assistants (PAs) had 18,563,085 patient visits in 2008 with the diagnosis of diabetes mellitus (DM).(1) This is a staggering number considering that it is estimated that 23.6 million people or 7.8% of the population have diabetes, of which 17.9 million are diagnosed and another 5.7 million remain undiagnosed.(2) Diabetes, the metabolic syndrome, and impaired glucose tolerance (also known as pre-diabetes) are all becoming more epidemic in the United States. From 1980 through 2006, the number of Americans with diabetes tripled, and rather than slowing, this increase is rising dramatically, primarily due to the obesity epidemic in this country.(3) DM is now the 5th leading cause of death in this country and is expected to increase further.(4)
The estimated diabetes costs in the United States in 2007 include direct medical costs of $116 billion, and indirect medical costs of $58 billion, for a total of $174 billion annually. After adjusting for population age and sex differences, average medical expenditures among people with diagnosed diabetes were 2.3 times higher than what expenditures would be in the absence of diabetes.(5) Diabetes is associated with an increased risk for a number of serious, frequently life-threatening complications including acute coronary syndromes, stroke, blindness, kidney disease and death.(6) Certain populations experience an even greater threat. Good diabetes control can help reduce these risks dramatically. Type 1 diabetes mellitus (T1DM) was previously called insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes. T1DM develops when the body's immune system destroys pancreatic beta cells, the only cells in the body that make the hormone insulin that regulates blood glucose. To survive, people with type 1 diabetes must have insulin delivered by injection or a pump. In adults, T1DM accounts for 5% to 10% of all diagnosed cases of diabetes. Although it may also be treated with insulin, Type 2 diabetes mellitus (T2DM) was previously called non–insulin-dependent diabetes mellitus (NIDDM) or adult onset diabetes. In adults, type 2 diabetes accounts for about 90% to 95% of all diagnosed cases of diabetes. It usually begins as insulin resistance, a disorder in which the cells do not use insulin properly. As the need for insulin rises, the pancreas gradually loses its ability to produce it. T2DM is associated with older age, obesity, family history of diabetes, history of gestational diabetes, impaired glucose metabolism, physical inactivity, and race/ethnicity. African Americans, Hispanic/Latino Americans, American Indians, and some Asian Americans and Native Hawaiians or Other Pacific Islanders are at particularly high risk for type 2 diabetes and its complications.Gestational diabetes is a form of glucose intolerance diagnosed during pregnancy. Women who have had gestational diabetes have a 40% to 60% chance of developing diabetes in the next 5–10 years. Other types of diabetes result from specific genetic conditions (such as maturity-onset diabetes of youth), surgery, medications, infections, pancreatic disease, and other illnesses. Such types of diabetes account for 1% to 5% of all diagnosed cases.Regardless of the type of diabetes, only 37 percent of patients were achieving the American Diabetes Association's (ADA) goal for blood glucose control – a hemoglobin A1c (A1C) blood test result of less than 7 percent, ADA's recommended "take action" level. More disturbing is the fact that less than 12 percent – and some sources estimate as little as 7 percent – of people with diagnosed diabetes meet the recommended goals for blood glucose, blood pressure, and cholesterol despite a great deal of research showing that controlling these conditions dramatically delays or prevents diabetes complications.(7)There is significant data that clinicians in general do not escalate treatments in patients, termed clinical inertia.(8) In diabetes care, the largest hurdle perceived by clinicians and patients alike is the initiation of insulin therapy. In spite of not achieving goal with multiple oral anti-diabetic agents, both groups are slow to escalate to insulin, in spite of the clear benefit. Those that do initiate insulin are frequently slow to escalate dosing appropriately. In this educational initiative, an expert panel will examine and discuss the standard of care with respect to state of the art treatment of diabetes. A series of case studies will be presented to help illustrate diagnostic and therapeutic management strategies, and the critical role of PAs in managing diabetes including early initiation of insulin in clinical practice. | | References | - American Academy of Physician Assistants Annual Survey. Available at http://www.aapa.org/images/stories/iudisorders2008.pdf; Accessed July 23, 2009.
- Centers for Disease Control and Prevention, 2007 National Diabetes Fact Sheet. Retrieved December 12, 2008 from http://www.cdc.gov/diabetes/pubs/estimates07.htm
- Centers for Disease Control and Prevention, Diabetes Data and Trends. Retrieved December 12, 2008 from http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm
- American Diabetes Association. Diabetes Care. 2005;28(supply 1):S4-S36
- Centers for Disease Control and Prevention, National Diabetes Fact Sheet. Retrieved December 12, 2008 from http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf
- American Diabetes Association Diabetes Statistics. Retrieved December 12, 2008 from http://www.diabetes.org/diabetes-statistics.jsp
- National Diabetes Information Clearinghouse, Diabetes Dateline. Retrieved December 12, 2008 from http://diabetes.niddk.nih.gov/about/dateline/spr04/1.htm
- Phillips LS, Branch WT, Cook CB, et al. Ann Intern Med. 2001;135:825-834.
| | |
Faculty
| | Lawrence Herman, MPA, RPA-C, DFAAPA Moderator Physician Assistant Senior Clinical Coordinator Assistant Professor Department of Physician Assistant Studies New York Institute of Technology Old Westbury, NY Director, Medical Education Island Medical Physicians, PC Hauppauge, NY | | | Charles Shaefer, Jr., MD, FACP, FCCP Internal Medicine Senior Partner University Primary Care Augusta, Georgia Assistant Clinical Professor of Medicine Medical College of Georgia Augusta, Georgia | | | Christopher M. Eten, MPAS, RPA-C
Physician Assistant
Westhampton Primary Care Center Westhampton Beach, NY | | | Intended Audience | | Physician Assistants | | |
Clinical Dialogue Program Description
| |
In this 25 minute Webcast, an expert panel will examine and discuss the standard of care with respect to state of the art treatment of diabetes. This Internet-based CME activity includes an optional pre-and post-survey, a CME post-test and program evaluation (feedback). CME credit will be awarded to those achieving a grade of 70% or higher on the post-test.
| | |
eCase Challenge Program Description
| | Two 20 minute text-based case challenge programs will provide PAs with a review of challenging cases where they will be asked to make decisions pertaining to the management of diabetes patients. At the conclusion of each case, there is a Clinical Pearl video that the participant can view which highlights the key take away messages from each program. This Internet-based CME activity includes an optional pre-and post-survey, a CME post-test and program evaluation (feedback). CME credit will be awarded to those achieving a grade of 70% or higher on the post-test. | | | Educational Objectives | |
At the conclusion of this activity, the physician assistant should be better able to:
| - Describe the risks for acquiring T2DM, along with strategies to consider in preventing the development of T2DM.
- Detail goals of current guidelines including A1C, cholesterol, and blood pressure, along with the rationale behind these goals.
- Describe the role of the primary care health professional in helping diabetics and their families make management decisions to best control their diabetes.
- Outline management strategies for prediabetes and the early stages of T2DM, including lifestyle changes and pharmacologic choices to best treat T2DM and control sequelae of DM.
- Evaluate and modify treatment options in the face of progressive worsening of T2DM, focusing upon the role of early insulin initiation.
- Outline the management decisions that must be made in consideration of referral to a team of diabetes specialists, including a primary care provider, registered diabetes educator, and endocrinologists in any point of the disease process.
| | | Accreditation Statements |  | | Each program in this initiative has been reviewed and is approved for a maximum of 0.5 hour of AAPA Category 1 CME credit by the Physician Assistant Review Panel. Physician assistants should claim only those hours actually spent participating in the CME activity. This program was planned in accordance with the AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Approval is valid for one year from the issue date of July 24, 2009. Participants may submit the self-assessment at any time during that period. | | |
Responsibility Statement
| | The American Academy of Physician Assistants takes responsibility for the content, quality, and scientific integrity of this CME activity. | | | Faculty Disclosures | | It is the policy of the American Academy of Physician Assistants to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following: | | Lawrence Herman, MPA, RPA-C, DFAAPA, has been a consultant for Amgen, Eli Lilly and Johnson & Johnson Diabetes Institute.
| | Charles Shaefer, Jr., MD, FACP, FCCP reports receiving honoraria from Amylin-Lilly, Daiichi-Sankyo, Forest, Novo-Nordisk, Sanofi-aventis and Takeda, and has been a consultant for Novartis, Pfizer and Sanofi-aventis.
| | Christopher M. Eten, MPAS, RPA-C, reports that he has no relationship with any commercial interests whose products or services may be mentioned during this presentation.
| | | Off-Label Discussion | | There are no references to unlabelled/unapproved uses of products in this program. | | Disclaimer | | The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients. | | |
Archived Presentation
| | The Clinical Dialogue and eCase Challenge will be archived for clinicians. CME credits will be provided by the AAPA from July 24, 2009 through July 31, 2010 for physician assistants at www.AAPA.org. | | | Obtaining CME Credits | | Upon completion of your participation in the program, physician assistants will be directed to www.AAPA.org to complete a post-test and receive your certificates. | | | Successful completion of the self-assessment by physician assistants is required to earn Category 1 CME credit. Successful completion is defined as a cumulative score of at least 70% correct. Upon successful completion of the post-test, the AAPA will issue a certificate of completion for your records. | | |
Technical Requirements
| | Processor Speed: 1.4 GHz P3 | | Memory: 256 MB RAM (20MB available) | | Operating Systems Supported: Windows 2000/XP, MAC | | Browsers Supported: Internet Explorer 5.5 or greater, Mozilla Firefox and Safari 3.525 or greater | |
Additional Requirements: Flash player 8.0 or greater, 800x600 Resolution or higher with 32-bit color
| | Connection Speed: 128 Kbps or better | | Adobe Acrobat 6.0 or greater | | | Sponsored by the American Academy of Physician Assistants |  | | | Supported through an educational grant from Novo-Nordisk | | | Produced by: |  | | |
© 2009 American Academy of Physician Assistants. All rights reserved.
|
|
|
|
|
|
|
|